CN106512064B - 一种具有抗菌性能的皮肤创伤敷料及其制备方法 - Google Patents
一种具有抗菌性能的皮肤创伤敷料及其制备方法 Download PDFInfo
- Publication number
- CN106512064B CN106512064B CN201710022060.7A CN201710022060A CN106512064B CN 106512064 B CN106512064 B CN 106512064B CN 201710022060 A CN201710022060 A CN 201710022060A CN 106512064 B CN106512064 B CN 106512064B
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- solution
- antibacterial
- fiber membrane
- wound dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 58
- 206010072170 Skin wound Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 57
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 57
- 239000000661 sodium alginate Substances 0.000 claims abstract description 57
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 57
- 239000012528 membrane Substances 0.000 claims abstract description 39
- 239000000835 fiber Substances 0.000 claims abstract description 32
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000004108 freeze drying Methods 0.000 claims abstract description 15
- 230000004048 modification Effects 0.000 claims abstract description 8
- 238000012986 modification Methods 0.000 claims abstract description 8
- 239000011159 matrix material Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 31
- 238000002791 soaking Methods 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 239000008055 phosphate buffer solution Substances 0.000 claims description 9
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 7
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 7
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 6
- 239000012304 carboxyl activating agent Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- ODVRLSOMTXGTMX-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione Chemical compound NCCN1C(=O)C=CC1=O ODVRLSOMTXGTMX-UHFFFAOYSA-N 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 21
- 230000035876 healing Effects 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- -1 serine phospholipid Chemical class 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种具有抗菌性能的皮肤创伤敷料及其制备方法,属于生物医学工程技术领域。本发明提供的皮肤创伤敷料为海绵状多孔膜结构,通过冷冻干燥的方法以海藻酸钠为基质制备出海藻酸钠纤维膜,再以表面修饰的方式将生物抗菌肽Cys‑KR12固定在纤维膜上制备可得。本发明所制得的皮肤创伤敷料制备方法简单,材料来源丰富,克服了现有抗菌敷料长期使用会产生耐药性、功能单一等不足,免疫原性低,具有良好的生物相容性、抗菌性和诱导修复功能,可以促进创面的愈合和上皮细胞的生长,有利于创面的再上皮化。
Description
技术领域
本发明涉及生物医学工程技术领域,具体涉及一种具有抗菌性能的皮肤创伤敷料及其制备方法。
背景技术
皮肤是人体与外界环境的屏障,保护体内各种组织和器官免受外界物理性、机械性、化学性以及病原微生物的侵袭。当皮肤受到损伤时,若不能及时愈合,伤口表面需及时覆盖敷料。感染是烧创伤护理领域最为普遍的并发症之一,会导致伤口出现大量的渗出液,分解细胞外基质蛋白及多种生长因子,阻碍表皮再生及伤口闭合,从而显著影响康复的进程,甚至有可能导致烧创伤患者死亡。全身应用抗生素的疗法,往往在伤口局部的药物浓度达不到防治感染的有效范围,另外也会加大药物剂量,增加副作用。使用适宜的抗菌敷料可以充分降低伤口的感染,同时全面促进伤口愈合。临床上普遍采用抗生素药物敷料对皮肤创面进行抗菌治疗,虽然抗生素抗菌起效迅速,但长期使用抗生素会使细菌产生耐药性。同时,临床治疗中应用的纳米创伤敷料主要是将纳米抗菌材料(如:纳米银、纳米氧化硅、纳米氧化锌和纳米氧化钦等)与棉织物复合制得,具有较强的抗菌性能,但生物相容性差,无法降解,不宜用于创面的长期覆盖。因此,研制出一种具有起效迅速、长期使用后无耐受性、具有良好生物相容性和安全性的广谱抗菌剂是该领域的发展方向和趋势。
抗菌肽具有广谱抗菌活性,对大多数革兰氏阳性菌、阴性菌和真菌具有很强的抑制作用。尤为重要的是抗菌肽对多药物耐受的细菌具有明显的杀灭作用,包括甲氯亚林耐受的金黄色葡萄球菌和万古霉素耐受的肠球菌。抗菌肽多数是带有正电荷,而细菌的细胞膜富含林芝酰甘油或丝氨酸磷脂之类的磷脂使其带有负电荷,所以两者之间极易发生电荷作用,进而使抗菌肽产生杀灭细菌的生物学效应。而哺乳类动物的细胞膜主要是由两性离子组成,细胞膜上不存在甾醇类分子使抗菌肽不易对哺乳动物细胞产生伤害。抗菌肽的高特异性也决定了其临床引用具有较高的安全性。
抗菌肽通过在细菌的细胞膜积累并发生构象的变化进而破坏膜结构的完整性,导致细胞内容物外流,细菌细胞破裂,同时存在一些胞内抗菌机制,如抑制核酸合成,干扰蛋白质和抑制细胞膜合成等。而且抗菌肽的抗菌过程迅速,在接触微生物数秒内就能发生,这是传统抗生素无法比拟的。
发明内容
本发明的目的在于针对现有抗菌敷料生物相容性低、长期使用会产生耐药性、功能单一、不具备诱导组织再生功能等不足,提供一种具有抗菌性能的皮肤创伤敷料及其制备方法。该方法制得的皮肤创伤敷料免疫原性低,具有良好的生物相容性和抗菌性能,同时具有诱导创面修复和创面再上皮化的能力,制备过程耗时短,方法简单,原料来源丰富。
为实现上述目的,其技术解决方案为:
一种具有抗菌性能的皮肤创伤敷料,所述皮肤创伤敷料为海绵状多孔膜结构,以海藻酸钠为基质,通过用冷冻干燥的方法制备出海藻酸钠纤维膜,再以表面修饰的方式将生物抗菌肽Cys-KR12固定在纤维膜上制备而成。
进一步的,所述海藻酸钠和抗菌肽抗菌肽Cys-KR12的重量份数比为10﹕0.1~0.5。
更进一步的,所述海藻酸钠的分子量为2~3×105g/mol。
一种具有抗菌性能的皮肤创伤敷料的制备方法,所述制备方法包括以下步骤:
(1)海藻酸钠纤维膜的制备和预处理;
(2)抗菌肽Cys-KR12的固定。
进一步的,所述海藻酸钠纤维膜的制备和预处理具体步骤如下:
(1)按配方量将海藻酸钠溶于离子水中,配成质量浓度为3%的海藻酸钠溶液;
(2)将配制所得的海藻酸钠溶液倒入一次性培养皿中,置于-20℃冰箱中24小时,然后降至-80℃冷冻干燥24小时,制得海藻酸钠纤维膜;
(3)将步骤(2)所制得的海藻酸钠纤维膜浸泡于质量浓度为2%的氯化钙溶液中2小时,再用去离子水冲洗2~3次,置于-20℃冰箱24小时,然后降至-80℃冷冻干燥24小时,完成预处理。
更进一步的,所述抗菌肽Cys-KR12的固定具体步骤如下:
(1)将1-(3-二甲氨基丙基)-3-乙基碳二亚胺溶于2-(N-吗啉代)乙磺酸中配成浓度为0.8mg/mL的EDS溶液,将N-羟基琥珀酰亚胺溶于2-(N-吗啉代)乙磺酸中配成浓度为1.2mg/mL的NHS溶液,然后将EDS溶液和NHS溶液两者等体积混合制得羧基活化剂;
(2)将预处理后的海藻酸钠纤维膜浸泡于步骤(1)所制得的羧基活化剂中,室温下反应30分钟,然后用磷酸盐缓冲溶液冲洗2~3次;
(3)将N-(2-氨基乙基)马来酰亚胺溶于磷酸盐缓冲溶液中,配制成浓度为0.2mg/mL的AME-PBS溶液;
(4)将步骤(2)处理后的海藻酸钠纤维膜浸泡于步骤(3)所配制的AME-PBS溶液中,室温下反应2小时,然后用去离子水冲洗2~3次;
(5)将抗菌肽Cys-KR12溶于磷酸盐缓冲溶液中配制成浓度为50~500μg/mL的溶液,然后将步骤(4)处理所得的海藻酸钠纤维膜浸泡于其中,室温下反应4小时,再用去离子水冲洗2~3次,置于-80℃冰箱中冷冻干燥24小时,制得具有抗菌性能的皮肤创伤敷料。
与现有技术相比,本发明具有以下有益效果:
(1)本发明所制得的皮肤创伤敷料具有广谱抗菌活性,对革兰氏阴性菌、革兰氏阳性菌和真菌均有较强的抑菌作用,且起效快(接触细菌后24小时,抑菌率均能达95%以上),长期使用后无耐受性;
(2)本发明所制得的皮肤创伤敷料是以海藻酸钠为基质,通过表面修饰将生物抗菌肽Cys-KR12固定在海藻酸钠纤维膜上,相比于负载抗菌成分的传统创伤敷料,该种敷料的抗菌时效较长,不存在因抗菌成分释放而导致敷料抗菌性能下降的问题;
(3)本发明所制得的皮肤创伤敷料具有良好的生物相容性,且具有诱导修复功能,可以促进创面的愈合和上皮细胞的生长,有利于创面的再上皮化;
(4)本发明的制备过程耗时短,工艺简单,原料来源丰富,易于实现产业化。
附图说明
图1为实施例1~3所制备的一种具有抗菌性能的皮肤创伤敷料和对比例的抗菌性能评价结果;
图2为实施例1~3所制备的一种具有抗菌性能的皮肤创伤敷料和对比例的细胞毒性评价结果。
具体实施方式
下面结合具体实施例对本发明的技术方案作进一步的说明。
实施例1
一种具有抗菌性能的皮肤创伤敷料,所述皮肤创伤敷料为海绵状多孔膜结构,以海藻酸钠为基质,通过用冷冻干燥的方法制备出海藻酸钠纤维膜,再以表面修饰的方式将生物抗菌肽Cys-KR12固定在纤维膜上制备而成。其中,所述海藻酸钠和抗菌肽抗菌肽Cys-KR12的重量份数比为10﹕0.1,所述的海藻酸钠的分子量为2~3×105g/mol。
实施例2
一种具有抗菌性能的皮肤创伤敷料,所述皮肤创伤敷料为海绵状多孔膜结构,以海藻酸钠为基质,通过用冷冻干燥的方法制备出海藻酸钠纤维膜,再以表面修饰的方式将生物抗菌肽Cys-KR12固定在纤维膜上制备而成。其中,所述海藻酸钠和抗菌肽抗菌肽Cys-KR12的重量份数比为10﹕0.25,所述的海藻酸钠的分子量为2~3×105g/mol。
实施例3
一种具有抗菌性能的皮肤创伤敷料,所述皮肤创伤敷料为海绵状多孔膜结构,以海藻酸钠为基质,通过用冷冻干燥的方法制备出海藻酸钠纤维膜,再以表面修饰的方式将生物抗菌肽Cys-KR12固定在纤维膜上制备而成。其中,所述海藻酸钠和抗菌肽抗菌肽Cys-KR12的重量份数比为10﹕0.5,所述的海藻酸钠的分子量为2~3×105g/mol。
实施例4
实施例1~3任一例中一种具有抗菌性能的皮肤创伤敷料,其制备方法的具体步骤如下:
1、海藻酸钠纤维膜的制备和预处理:
(1)按配方量将海藻酸钠溶于离子水中,配成质量浓度为3%的海藻酸钠溶液;
(2)将配制所得的海藻酸钠溶液倒入一次性培养皿中,置于-20℃冰箱中24小时,然后降至-80℃冷冻干燥24小时,制得海藻酸钠纤维膜;
(3)将步骤(2)所制得的海藻酸钠纤维膜浸泡于质量浓度为2%的氯化钙溶液中2小时,再用去离子水冲洗2~3次,置于-20℃冰箱24小时,然后降至-80℃冷冻干燥24小时,完成预处理。
2、抗菌肽Cys-KR12的固定:
(1)将1-(3-二甲氨基丙基)-3-乙基碳二亚胺溶于2-(N-吗啉代)乙磺酸中配成浓度为0.8mg/mL的EDS溶液,将N-羟基琥珀酰亚胺溶于2-(N-吗啉代)乙磺酸中配成浓度为1.2mg/mL的NHS溶液,然后将EDS溶液和NHS溶液两者等体积混合制得羧基活化剂;
(2)将预处理后的海藻酸钠纤维膜浸泡于步骤(1)所制得的羧基活化剂中,室温下反应30分钟,然后用磷酸盐缓冲溶液冲洗2~3次;
(3)将N-(2-氨基乙基)马来酰亚胺溶于磷酸盐缓冲溶液中,配制成浓度为0.2mg/mL的AME-PBS溶液;
(4)将步骤(2)处理后的海藻酸钠纤维膜浸泡于步骤(3)所配制的AME-PBS溶液中,室温下反应2小时,然后用去离子水冲洗2~3次;
(5)将抗菌肽Cys-KR12溶于磷酸盐缓冲溶液中配制成浓度为50~500μg/mL的溶液,然后将步骤(4)处理所得的海藻酸钠纤维膜浸泡于其中,室温下反应4小时,再用去离子水冲洗2~3次,置于-80℃冰箱中冷冻干燥24小时,制得具有抗菌性能的皮肤创伤敷料。
实施例5
对比例:一种含纳米银的海藻酸钠基抗菌医用敷料(参考申请号为CN201310165016.3所公开的一种含纳米银的海藻酸钠基抗菌医用敷料及其制备方法的制备方法所制得)。
实验组1~3:实施例1~3所得的具有抗菌性能的皮肤创伤敷料,采用实施例4的方法制备而成。
将上述实施例1~3所制备的具有抗菌性能的皮肤创伤敷料与对比例进行抗菌能力评价试验,对比实施例1~3和对比例对大肠杆菌、金华葡萄球菌和白色念珠菌接触24小时后的抑菌效果。实验结果如图1所示。
从图1实验结果可见,实施例1~3在与大肠杆菌、金华葡萄球菌和白色念珠菌接触24小时后抑菌率达到95%以上,而对比例仅在60%左右,证明实施例1~3均具有强效、作用时间快的广谱抗菌性能。
实施例6
对比例:一种含纳米银的海藻酸钠基抗菌医用敷料(参考申请号为CN201310165016.3所公开的一种含纳米银的海藻酸钠基抗菌医用敷料及其制备方法的制备方法所制得)。
实验组1~3:实施例1~3所得的具有抗菌性能的皮肤创伤敷料,采用实施例4的方法制备而成。
将上述实施例1~3所制备的具有抗菌性能的皮肤创伤敷料与对比例进行细胞毒性评价实验(按国标GB/T 16886.5-2003进行实验),对比实施例1~3和对比例。实验结果如图2所示。
细胞毒性检测结果显示实施例1~3在与人成纤维细胞共培养24小时和48小时后,其对应的细胞相对增殖率均在90%以上,细胞毒性评级为0级,证明其具有良好的细胞相容性。而对比例与人成纤维细胞共培养24小时和48小时后,其对应细胞相对增殖率在70%左右,细胞毒性评级为3级,具有严重的细胞毒性。此外,共培养时间的延长实施例1~3的相对相比增殖率均有明显提高,实施例2和3在48小时后其细胞相对增殖率均较阴性组要高(均高于100%),证明采用本发明所公开的制备方法所制得的皮肤创伤敷料具有促进人成纤维细胞的生长,有利于创面的愈合。
实施例7
对比例:为市售的海藻酸钠敷料。
实验组1~3:为实施例1~3所制备的具有抗菌性能的皮肤创伤敷料与对比例进行动物伤口修复实验,对比实验组和对比例对创面的修复效果,实验结果如表1所示:
表1 伤口修复实验结果
实施例1 | 实施例2 | 实施例3 | 对比例 | |
愈合时间/天 | 7 | 6 | 7 | 14 |
愈合情况 | 伤口愈合过程中无炎症、流脓等状况发生,愈合后无瘢痕产生。 | 伤口愈合过程中无炎症、流脓等状况发生,愈合后无瘢痕产生。 | 伤口愈合过程中无炎症、流脓等状况发生,愈合后无瘢痕产生。 | 伤口伴有炎症、流脓等状况,伤口愈合后有明显的瘢痕产生。 |
由上表可知,实施例1~3所制备的具有抗菌性能的皮肤创伤敷料在伤口的愈合过程中能有效防止因细菌感染,而且能有效地缩短伤口愈合的时间。
以上结合实施例对本发明做出详细说明,但本发明不局限于所描述的实施方式。对本领域的普通技术人员而言,在本发明的原理和技术思想的范围内,对这些实施方式进行多种变化、修改、替换和变型仍落入本发明的保护范围内。
Claims (2)
1.一种具有抗菌性能的皮肤创伤敷料,其特征在于,所述皮肤创伤敷料为海绵状多孔膜结构,以海藻酸钠为基质,通过用冷冻干燥的方法制备出海藻酸钠纤维膜,再以表面修饰的方式将生物抗菌肽Cys-KR12固定在纤维膜上制备而成,所述海藻酸钠和抗菌肽Cys-KR12的重量份数比为10﹕0.1~0.5,所述一种具有抗菌性能的皮肤创伤敷料的制备方法包括以下步骤:
第一步:海藻酸钠纤维膜的制备和预处理,所述海藻酸钠纤维膜的制备和预处理的具体步骤为:
(1)按配方量将海藻酸钠溶于离子水中,配成质量浓度为3%的海藻酸钠溶液;
(2)将配制所得的海藻酸钠溶液倒入一次性培养皿中,置于-20℃冰箱中24小时,然后降至-80℃冷冻干燥24小时,制得海藻酸钠纤维膜;
(3)将步骤(2)所制得的海藻酸钠纤维膜浸泡于质量浓度为2%的氯化钙溶液中2小时,再用去离子水冲洗2~3次,置于-20℃冰箱24小时,然后降至-80℃冷冻干燥24小时,完成预处理;
第二步:抗菌肽Cys-KR12的固定,所述抗菌肽Cys-KR12的固定的具体步骤为:
(1)将1-(3-二甲氨基丙基)-3-乙基碳二亚胺溶于2-(N-吗啉代)乙磺酸中配成浓度为0.8mg/mL的EDS溶液,将N-羟基琥珀酰亚胺溶于2-(N-吗啉代)乙磺酸中配成浓度为1.2mg/mL的NHS溶液,然后将EDS溶液和NHS溶液两者等体积混合制得羧基活化剂;
(2)将预处理后的海藻酸钠纤维膜浸泡于步骤(1)所制得的羧基活化剂中,室温下反应30分钟,然后用磷酸盐缓冲溶液冲洗2~3次;
(3)将N-(2-氨基乙基)马来酰亚胺溶于磷酸盐缓冲溶液中,配制成浓度为0.2mg/mL的AME-PBS溶液;
(4)将步骤(2)处理后的海藻酸钠纤维膜浸泡于步骤(3)所配制的AME-PBS溶液中,室温下反应2小时,然后用去离子水冲洗2~3次;
(5)将抗菌肽Cys-KR12溶于磷酸盐缓冲溶液中配制成浓度为50~500μg/mL的溶液,然后将步骤(4)处理所得的海藻酸钠纤维膜浸泡于其中,室温下反应4小时,再用去离子水冲洗2~3次,置于-80℃冰箱中冷冻干燥24小时,制得具有抗菌性能的皮肤创伤敷料。
2.根据权利要求1所述的一种具有抗菌性能的皮肤创伤敷料,其特征在于,所述海藻酸钠的分子量为2~3×105g/mol。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022060.7A CN106512064B (zh) | 2017-01-12 | 2017-01-12 | 一种具有抗菌性能的皮肤创伤敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022060.7A CN106512064B (zh) | 2017-01-12 | 2017-01-12 | 一种具有抗菌性能的皮肤创伤敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106512064A CN106512064A (zh) | 2017-03-22 |
CN106512064B true CN106512064B (zh) | 2019-12-10 |
Family
ID=58335434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710022060.7A Expired - Fee Related CN106512064B (zh) | 2017-01-12 | 2017-01-12 | 一种具有抗菌性能的皮肤创伤敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106512064B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107519535B (zh) * | 2017-09-28 | 2020-05-05 | 武汉理工大学 | 可降解海藻酸钠/丝素双层皮肤组织工程支架材料及其制备方法 |
CN108210979B (zh) * | 2018-01-28 | 2020-09-29 | 山东东贝医药科技有限公司 | 一种医用杀菌纤维敷料 |
CN108721122A (zh) * | 2018-06-09 | 2018-11-02 | 江苏海尔滋生物科技有限公司 | 一种牙根管清创、消毒生物胶生物材料及其制备方法 |
CN108904868A (zh) * | 2018-08-13 | 2018-11-30 | 安徽创孚医疗科技有限公司 | 一种双联抗菌及抗凝敷料的制备方法 |
KR102162474B1 (ko) * | 2018-12-26 | 2020-10-06 | 광주여자대학교 산학협력단 | 방부제로 인간 유래 항균펩타이드를 함유하는 화장품 |
CN110404103A (zh) * | 2019-07-22 | 2019-11-05 | 华南理工大学 | 一种糖尿病足修复纳米膜及其制备方法 |
CN110917391A (zh) * | 2019-12-26 | 2020-03-27 | 广东泰宝医疗科技股份有限公司 | 一种多肽修饰海藻酸钠/pva水凝胶敷料及其制备方法 |
CN113069556B (zh) * | 2021-04-12 | 2022-04-08 | 青岛大学附属医院 | 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法 |
CN115337455B (zh) * | 2022-08-11 | 2023-12-22 | 成都慧捷斯生物科技有限公司 | 一种用于皮肤及粘膜损伤修复的生物陶瓷材料及其制备方法 |
CN117160254B (zh) * | 2023-10-31 | 2024-01-23 | 湖南沁森高科新材料有限公司 | 一种反渗透复合膜及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101401975A (zh) * | 2008-11-07 | 2009-04-08 | 中国人民解放军第三军医大学第三附属医院 | 载缓释抗菌肽组织工程骨及其制作方法 |
CN103611181A (zh) * | 2013-10-25 | 2014-03-05 | 无锡灵锡医疗器械科技有限公司 | 一种抗菌肽水凝胶及其制备方法 |
CN104189942A (zh) * | 2014-09-09 | 2014-12-10 | 东华大学 | 一种抗菌型创伤敷料及其制备方法 |
CN104383580A (zh) * | 2014-10-30 | 2015-03-04 | 河北考力森生物科技有限公司 | 一种含海藻酸盐/胶原膜的制备方法 |
CN104497336A (zh) * | 2014-12-03 | 2015-04-08 | 浙江海洋学院 | 一种黄鲫蛋白抗菌肽-纳米氧化锌膜的制备方法 |
CN105920652A (zh) * | 2016-04-29 | 2016-09-07 | 华南理工大学 | 一种共价接枝抗菌多肽的抗菌凝胶及其制备方法 |
-
2017
- 2017-01-12 CN CN201710022060.7A patent/CN106512064B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101401975A (zh) * | 2008-11-07 | 2009-04-08 | 中国人民解放军第三军医大学第三附属医院 | 载缓释抗菌肽组织工程骨及其制作方法 |
CN103611181A (zh) * | 2013-10-25 | 2014-03-05 | 无锡灵锡医疗器械科技有限公司 | 一种抗菌肽水凝胶及其制备方法 |
CN104189942A (zh) * | 2014-09-09 | 2014-12-10 | 东华大学 | 一种抗菌型创伤敷料及其制备方法 |
CN104383580A (zh) * | 2014-10-30 | 2015-03-04 | 河北考力森生物科技有限公司 | 一种含海藻酸盐/胶原膜的制备方法 |
CN104497336A (zh) * | 2014-12-03 | 2015-04-08 | 浙江海洋学院 | 一种黄鲫蛋白抗菌肽-纳米氧化锌膜的制备方法 |
CN105920652A (zh) * | 2016-04-29 | 2016-09-07 | 华南理工大学 | 一种共价接枝抗菌多肽的抗菌凝胶及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Bilayered Films Based on Novel Polymer Derivative for Improved Ocular Therapy of Gatifloxacin;Naval Dinesh Aher et al;《The Scientific World Journal》;20140102;第2014卷;正文第2页第2.2.1节 * |
CecropinB抗菌肽接枝丝素蛋白膜的制备和表征;白利强等;《高等学校化学学报》;20070831;第28卷(第8期);正文第1593页前言,,第1594页第1.2节 * |
Also Published As
Publication number | Publication date |
---|---|
CN106512064A (zh) | 2017-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106512064B (zh) | 一种具有抗菌性能的皮肤创伤敷料及其制备方法 | |
Zhang et al. | Functional biomaterials for treatment of chronic wound | |
Priya et al. | Bilayer cryogel wound dressing and skin regeneration grafts for the treatment of acute skin wounds | |
Thattaruparambil Raveendran et al. | Ciprofloxacin-and fluconazole-containing fibrin-nanoparticle-incorporated chitosan bandages for the treatment of polymicrobial wound infections | |
Napavichayanun et al. | Interaction and effectiveness of antimicrobials along with healing-promoting agents in a novel biocellulose wound dressing | |
Pérez-Rafael et al. | Nanoparticle-driven self-assembling injectable hydrogels provide a multi-factorial approach for chronic wound treatment | |
Gupta et al. | Efficacy of Chitosan in promoting wound healing in extraction socket: A prospective study | |
KR101548752B1 (ko) | 반흔화에 있어서의 신규한 활성 기질 및 이들의 용도 | |
CN110876815A (zh) | 一种负载富血小板血浆和抗菌肽的水凝胶及其制备方法和应用 | |
CN113174060B (zh) | 一种海藻酸-壳寡糖-氧化锌复合水凝胶及其制备方法和应用 | |
Fang et al. | Development of a Chitosan–Vaseline Gauze Dressing with Wound-Healing Properties in Murine Models | |
US11938230B2 (en) | Hemostatic material and wound dressing containing same | |
Cheng et al. | Preparation of norfloxacin-grafted chitosan antimicrobial sponge and its application in wound repair | |
US20190038643A1 (en) | Hydrogen Sulfide (H2S) Releasing Donor Compound For Dermal Wound Regeneration | |
CN110917391A (zh) | 一种多肽修饰海藻酸钠/pva水凝胶敷料及其制备方法 | |
KR20100028608A (ko) | 조직수복재료로서의 콜라겐 기반 매트릭스 및 이의 제조방법 | |
RU2372922C1 (ru) | Способ лечения глубокого ожога кожи | |
Li et al. | A promising wound dressing from regenerated silk fibroin sponge with sustain-ed release of silver nanoparticles | |
JPH09278803A (ja) | 医療用手当材 | |
Hartmeier et al. | Hydrogel dressings for chronic wound healing in diabetes: Beyond hydration | |
CN117561073A (zh) | 新型生物活性肽组合和其用途 | |
Zhang et al. | Acellular embryoid body and hydroxybutyl chitosan composite hydrogels promote M2 macrophage polarization and accelerate diabetic cutaneous wound healing | |
Peng et al. | Hydroxypropyl chitosan/ε-poly-l-lysine based injectable and self-healing hydrogels with antimicrobial and hemostatic activity for wound repair | |
WO2020131806A1 (en) | Wound dressings including pvp-citric acid copolymer | |
CN113058068B (zh) | 一种壳聚糖季铵盐掺杂镁离子抗菌敷料的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191210 |